Los Angeles Capital Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Los Angeles Capital Management’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,859	Closed	-$403K	–	1262
2023 Q2	$403K	Sell	1,859 -2,112	-53%	-$452K	﹤0.01%	915
2023 Q1	$721K	Sell	3,971 -480	-11%	-$91.8K	﹤0.01%	755
2022 Q4	$875K	Sell	4,451 -456	-9%	-$97.8K	﹤0.01%	740
2022 Q3	$1.1M	Buy	+4,907	New	+$993K	0.01%	661
2021 Q1	–	Sell	-2,880	Closed	-$293K	–	1669
2020 Q4	$293K	Sell	2,880 -150	-5%	-$13.9K	﹤0.01%	1382
2020 Q3	$234K	Buy	+3,030	New	+$258K	﹤0.01%	1352

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Los Angeles Capital Management's KRTX Position: Q3 2023 in Review

Los Angeles Capital Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2023, closing a stake of 1,859 shares — an estimated $403K sold.

Los Angeles Capital Management first reported a position in KRTX in Q3 2020 and held it in 6 quarters. The position peaked at $1.1M in Q3 2022. 256 funds tracked by Wall St. Rank hold KRTX as of Q3 2023.

Los Angeles Capital Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Los Angeles Capital Management sold 1,859 Karuna Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $403K.
Los Angeles Capital Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2020 and held it in 6 quarters.
Los Angeles Capital Management's Karuna Therapeutics, Inc. Common Stock position peaked at $1.1M in Q3 2022.
256 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Los Angeles Capital Management's 13F filing for Q3 2023, filed 6 Nov 2023.